| Literature DB >> 27453734 |
Fangfang Zeng1, Linuo Zhou1, Zihui Tang2.
Abstract
BACKGROUND: The aim of this study was to investigate the association and interaction of metabolic syndrome (MetS) and estrogen receptor alpha 1 (ESR1) gene polymorphisms on cardiovascular autonomic neuropathy (CAN).Entities:
Keywords: Cardiovascular autonomic neuropathy; Estrogen receptor alpha gene; Interaction analysis; Metabolic syndrome
Year: 2016 PMID: 27453734 PMCID: PMC4957320 DOI: 10.1186/s13098-016-0155-3
Source DB: PubMed Journal: Diabetol Metab Syndr ISSN: 1758-5996 Impact factor: 3.320
The clinical baseline characteristics of individuals
| Variable | non-MetS | MetS | Entire sample | p value* |
|---|---|---|---|---|
|
| ||||
| N | 1194 | 783 | 1977 | |
| Age years | 59.8 ± 8.85 | 61.56 ± 8.37 | 60.5 ± 8.71 | <0.001 |
| Gender male, % | 409 (34.25 %) | 258 (32.95 %) | 667 (33.74 %) | 0.396 |
| Height cm | 161.5 ± 7.89 | 161.48 ± 7.79 | 161.49 ± 7.85 | 0.942 |
| Weight kg | 60.41 ± 9.78 | 67.69 ± 10.5 | 63.3 ± 10.68 | <0.001 |
| SBP mmHg | 122.61 ± 17.33 | 135.52 ± 18.34 | 127.71 ± 18.82 | <0.001 |
| DBP mmHg | 77.82 ± 9.38 | 82.8 ± 9.38 | 79.79 ± 9.69 | <0.001 |
|
| ||||
| Smoking yes | 182 (15.24 %) | 122 (15.58 %) | 304 (15.38 %) | 0.773 |
| HTN yes | 371 (31.07 %) | 557 (71.14 %) | 928 (46.94 %) | <0.001 |
| DM yes | 112 (9.39 %) | 307 (39.21 %) | 419 (21.2 %) | <0.001 |
| CAN yes | 173 (14.49 %) | 190 (24.27 %) | 363 (18.36 %) | <0.001 |
|
| ||||
| FPG mmol/L | 5.01 ± 1.27 | 6.19 ± 2.16 | 5.48 ± 1.78 | <0.001 |
| PBG mmol/L | 6.63 ± 2.87 | 9.08 ± 4.02 | 7.6 ± 3.58 | <0.001 |
| FINS uml/L | 6.07 ± 10.53 | 9.07 ± 14.08 | 7.26 ± 12.16 | <0.001 |
| TC mmol/L | 5.31 ± 0.96 | 5.33 ± 1.07 | 5.32 ± 1 | 0.603 |
| TG mmol/L | 1.35 ± 0.66 | 2.26 ± 1.14 | 1.71 ± 0.99 | <0.001 |
| HDL mmol/L | 1.46 ± 0.32 | 1.2 ± 0.26 | 1.36 ± 0.33 | <0.001 |
| LDL mmol/L | 3.18 ± 0.76 | 3.21 ± 0.8 | 3.19 ± 0.78 | 0.212 |
| SCr μmol/L | 76.56 ± 28.72 | 79.14 ± 22.9 | 77.58 ± 26.59 | 0.003 |
| UA μmol/L | 265.96 ± 78.37 | 302.66 ± 87.82 | 280.51 ± 84.17 | <0.001 |
|
| ||||
| HR bpm | 71.57 ± 9.92 | 73.96 ± 10.34 | 72.52 ± 10.16 | <0.001 |
| TP ms2 | 938.73 ± 728.92 | 788.78 ± 668.07 | 879.34 ± 709.16 | <0.001 |
| LF ms2 | 210.37 ± 219.54 | 164.72 ± 189.4 | 192.29 ± 209.3 | <0.001 |
| HF ms2 | 203.82 ± 241.68 | 155.52 ± 183.24 | 184.69 ± 221.63 | <0.001 |
| LF/HF | 1.67 ± 2.05 | 1.74 ± 1.87 | 1.7 ± 1.98 | 0.307 |
|
| ||||
| rs9340799 | 237 (19.97 %) | 147 (19.08 %) | 384 (19.62 %) | 0.495 |
* Difference analysis between non-MetS and MetS groups
SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, PBG plasma blood glucose, FINS fasting blood insulin, TC serum total cholesterol, TG triglyceride, UA uric acid, HDL high-density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, SCr serum creatinine, UA uric acid, HR heart rate, TP total power of variance, LF low frequency, HF high frequency, HTN hypertension, MetS metabolic syndrome, DM diabetes mellitus, CAN cardiovascular autonomic neuropathy, SNP single nucleotide polymorphism
Information of single nucleotide polymorphism of ESR1 and its primer
| SNP | Gene | CH | Allele | MAFCEU | MAFHCB | MAFTPS | HWE |
|---|---|---|---|---|---|---|---|
| rs9340799 |
| 6 | G/A | 0.217 | 0.306 | 0.196 | 0.451 |
| Up-stream | CATCTGAGTTCCAAATGTCC | ||||||
| Down-stream | GGATGAGCATTGGTCTCTAA | ||||||
SNP single nucleotide polymorphism, CH chromosome, MAF minor allele frequency in Utah residents with Northern and Western European ancestry sample, MAF minor allele frequency in Han Chinese in Beijing sample, MAF minor allele frequency in the present sample, HWE p value from Hardy–Weinberg Equilibrium test in our sample
Multiple variables analysis for metabolic syndrome and rs9340799 for cardiovascular autonomic neuropathy
| Variables |
| S.E. | p value |
| 95.0 % CI |
|---|---|---|---|---|---|
| MetS | 0.589 | 0.087 | <0.001 | 1.802 | 1.521–2.136 |
| rs9340799 | −0.114 | 0.109 | 0.299 | 0.893 | 0.720–1.106 |
MetS metabolic syndrome, BMI body mass index, and multiple variables logistic model adjusted for age, gender, PBG, FINS and renal functions
The interaction analysis of MetS and rs9340799 for CAN
| Variables |
| S.E. | p value |
| 95.0 % CI |
|---|---|---|---|---|---|
| MetS | 0.551 | 0.092 | 0.001 | 1.735 | 1.449–2.079 |
| rs9340799 | −0.354 | 0.259 | 0.226 | 0.702 | 0.314–1.159 |
| MetS by rs9340799 | 0.409 | 0.219 | 0.062 | 1.505 | 0.980–2.312 |
| RERI | 0.396 | 0.262–0.598 | |||
| AP | 0.216 | −0.784–1.216 | |||
| S | 1.906 | 0.905–4.015 | |||
MetS metabolic syndrome, RERI relative excess risk due to interaction, AP proportion attributable to interaction, S synergy index; and multiple variables logistic model adjusted for age, gender, PBG, FINS and renal functions
Fig. 1Interaction analysis of ESR1 (rs9340799) and metabolic syndrome for CAN. Interaction of MetS and rs9340799 (MetS*rs9340799 ORGEI = 1.505, 95 % CI 0.98–2.312, p = 0.062)